UA49847C2 - ПОХІДНІ ІМІДАЗОЛУ, ЩО МАЮТЬ СПОРІДНЕНІСТЬ ДО АКТИВНОСТІ <font face="Symbol">a</font>2-РЕЦЕПТОРІВ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ - Google Patents

ПОХІДНІ ІМІДАЗОЛУ, ЩО МАЮТЬ СПОРІДНЕНІСТЬ ДО АКТИВНОСТІ <font face="Symbol">a</font>2-РЕЦЕПТОРІВ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ

Info

Publication number
UA49847C2
UA49847C2 UA98031588A UA98031588A UA49847C2 UA 49847 C2 UA49847 C2 UA 49847C2 UA 98031588 A UA98031588 A UA 98031588A UA 98031588 A UA98031588 A UA 98031588A UA 49847 C2 UA49847 C2 UA 49847C2
Authority
UA
Ukraine
Prior art keywords
alkyl
hydrogen
affinity
different
imidazole derivatives
Prior art date
Application number
UA98031588A
Other languages
English (en)
Russian (ru)
Inventor
Арто Кар'ялайнен
Пааво Хухтала
Юха-Матті Савола
Зігфрід Вурстер
Майре Елоранта
Мааріт Хілліля
Раймо САКСЛУНД
Віктор Коккрофт
Ар'я Кар'ялайнен
Original Assignee
Оріон Корпорейшн
Орион Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оріон Корпорейшн, Орион Корпорейшн filed Critical Оріон Корпорейшн
Publication of UA49847C2 publication Critical patent/UA49847C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Abstract

Описані похідні імідазолу формули (І), , (І) в якій n = 0 або 1, R1 означає гідроген або С1-С4-алкіл, R2 означає гідроген, або R2 і R3 разом утворюють подвійний зв'язок, R3 означає гідроген або С1-С4-алкіл, або R2 і R3 разом утворюють подвійний зв'язок, R4 означає гідроген, С1-С4-алкіл, гідроксильну групу або С1-С4-алкоксигрупу, R5 означає гідроген або С1-С4-алкіл, або R4 і R5 разом з атомом карбону, з яким вони сполучені, утворюють карбонільну групу, R6, R7 і R8 однакові або різні і означають незалежно гідроген, С1-С4-алкіл або С2-С4-алкеніл, С3-С7-циклоалкіл, гідроксильну групу, С1-С4-алкоксил, С1-С4-гідроксіалкіл, тіол, С1-С4-алкілтіогрупу, С1-С4-алкілтіол, галоген, трифлуорметил, нітрогрупу або необов'язково заміщену аміногрупу, Х означає -СНR9-(СНR10)m - m = 0 або 1, а R9 і R10 однакові або різні і означають незалежно гідроген або С1-С4-алкіл; або їх фармацевтичнo придатний естер або сіль; їх отримання, застосування і фармацевтичні композиції, що їх містять. Ці сполуки мають спорідненість відносно альфа2-рецепторів і застосовні, наприклад у лікуванні гіпертензії, глаукоми, хронічного і гострого болю, мігрені, діареї, простуди (нежиті), ішемії, звикання до хімічних речовин, тривоги, особливо доопераційної тривоги, і різних неврологічних, м'язово-скелетних, психічних і пов'язаних з пізнавальною здатністю порушень або як допоміжний засіб при анестезії.
UA98031588A 1995-10-03 1996-10-02 ПОХІДНІ ІМІДАЗОЛУ, ЩО МАЮТЬ СПОРІДНЕНІСТЬ ДО АКТИВНОСТІ <font face="Symbol">a</font>2-РЕЦЕПТОРІВ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ UA49847C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9520150.5A GB9520150D0 (en) 1995-10-03 1995-10-03 New imidazole derivatives
PCT/FI1996/000518 WO1997012874A1 (en) 1995-10-03 1996-10-02 Imidazole derivatives having affinity for alpha2 receptors activity

Publications (1)

Publication Number Publication Date
UA49847C2 true UA49847C2 (uk) 2002-10-15

Family

ID=10781676

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98031588A UA49847C2 (uk) 1995-10-03 1996-10-02 ПОХІДНІ ІМІДАЗОЛУ, ЩО МАЮТЬ СПОРІДНЕНІСТЬ ДО АКТИВНОСТІ <font face="Symbol">a</font>2-РЕЦЕПТОРІВ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ

Country Status (30)

Country Link
US (2) US6313311B1 (uk)
EP (1) EP0888309B1 (uk)
JP (1) JP4129891B2 (uk)
KR (1) KR19990064013A (uk)
CN (1) CN1068592C (uk)
AT (1) ATE234819T1 (uk)
AU (1) AU708002B2 (uk)
BG (1) BG63916B1 (uk)
CA (1) CA2231535C (uk)
CZ (1) CZ291576B6 (uk)
DE (1) DE69626862T2 (uk)
DK (1) DK0888309T3 (uk)
EE (1) EE04436B1 (uk)
ES (1) ES2195013T3 (uk)
GB (1) GB9520150D0 (uk)
HK (1) HK1014951A1 (uk)
HU (1) HU224197B1 (uk)
IL (1) IL123721A (uk)
LT (1) LT4460B (uk)
LV (1) LV12108B (uk)
NO (1) NO311024B1 (uk)
NZ (1) NZ319169A (uk)
PL (1) PL189110B1 (uk)
PT (1) PT888309E (uk)
RO (1) RO120409B1 (uk)
RU (1) RU2188194C2 (uk)
SI (1) SI9620111B (uk)
SK (1) SK283542B6 (uk)
UA (1) UA49847C2 (uk)
WO (1) WO1997012874A1 (uk)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
AU2002254265B2 (en) * 1997-12-04 2008-05-15 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
IL136388A0 (en) * 1997-12-04 2001-06-14 Allergan Sales Inc Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors
WO2000018400A1 (en) * 1998-09-28 2000-04-06 Orion Corporation Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
EP1196168A2 (en) * 1999-06-25 2002-04-17 Orion Corporation Method of admistering an imidazole derivative to obtain analgesia
WO2001030347A1 (en) 1999-10-29 2001-05-03 Orion Corporation Treatment or prevention of hypotension and shock
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
WO2001085698A1 (en) * 2000-05-08 2001-11-15 Orion Corporation New polycyclic indanylimidazoles with alpha2 adrenergic activity
TW200306783A (en) * 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
FR2839719B1 (fr) * 2002-05-16 2004-08-06 Pf Medicament Nouveaux composes imidazoliques, leur procede de preparation et leur utilisation a titre de medicaments
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
DE102004035322A1 (de) * 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
BRPI0615307A2 (pt) 2005-08-25 2009-08-04 Schering Corp agonistas de adrenorreceptor alfa2c
DE602006016303D1 (de) 2005-08-25 2010-09-30 Pharmacopeia Llc 3,4-dihydro-2H-benzoÄ1,4Üoxazin- und 3,4-dihydro-2H-benzoÄ1,4Üthiazin-VERBINDUNGEN ALS ALPHA2C-ADRENOREZEPTOR-ANTAGONISTEN
CA2637261A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders
CA2666762C (en) 2006-10-19 2014-12-30 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
JP5064511B2 (ja) 2006-11-02 2012-10-31 エフ．ホフマン−ラ ロシュ アーゲー 痕跡アミン関連受容体調節剤としての置換２−イミダゾール
RU2456281C2 (ru) 2006-11-16 2012-07-20 Ф. Хоффманн-Ля Рош Аг Замещенные 4-имидазолы, способ их получения и их применение
AU2007332641A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR)
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
RU2473545C2 (ru) 2007-02-02 2013-01-27 Ф.Хоффманн-Ля Рош Аг Новые 2-аминооксазолины в качестве лигандов taar1 для заболеваний цнс
ATE530547T1 (de) 2007-02-13 2011-11-15 Schering Corp Derivate und analoge von chroman als funktionell selektive alpha2c-adrenorezeptor-agonisten
CA2678072A1 (en) 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
MX2009008775A (es) 2007-02-13 2010-03-01 Schering Corp Agonistas de adrenorreceptores alfa2c funcionalmente selectivos.
KR101335845B1 (ko) 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
BRPI0812840A2 (pt) 2007-07-02 2014-12-09 Hoffmann La Roche 2-imidazolinas
JP2010531836A (ja) 2007-07-03 2010-09-30 エフ．ホフマン−ラ ロシュ アーゲー ４−イミダゾリン及びそれらの抗うつ剤としての使用
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
WO2009019149A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US8383818B2 (en) 2008-02-21 2013-02-26 Merck Sharp & Dohme Corp. Functionally selective alpha2C adrenoreceptor agonists
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2010042473A1 (en) 2008-10-07 2010-04-15 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
US20110021588A1 (en) 2009-05-15 2011-01-27 Recro Pharma, Inc. Sublingual dexmeditomidine compositions and methods of use thereof
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8673950B2 (en) 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
PE20142314A1 (es) 2011-12-11 2015-01-23 Recro Pharma Inc Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
US9181230B2 (en) * 2012-01-12 2015-11-10 Hoffmann-La Roche Inc. Morpholine compounds and uses thereof
HUE037689T2 (hu) 2012-09-14 2018-09-28 Hoffmann La Roche Pirazol-karboxamid származékok mint TAAR-modulátorok különféle rendellenességek, mint például depresszió, cukorbetegség és Parkinson-kór kezelésében történõ alkalmazásra
ES2605632T3 (es) 2012-09-17 2017-03-15 F. Hoffmann-La Roche Ag Derivados triazol carboxamida
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
KR101909845B1 (ko) 2014-08-27 2018-10-18 에프. 호프만-라 로슈 아게 중추신경계 장애의 치료를 위한 치환된 피라지노[2,1-a]이소퀴놀린 유도체
CN107001259B (zh) 2014-08-27 2019-12-06 豪夫迈·罗氏有限公司 作为taar配体的取代的氮杂环丁烷衍生物
MY195528A (en) 2016-03-17 2023-01-30 Hoffmann La Roche 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636002A (en) * 1969-12-15 1972-01-18 Janssen Pharmaceutica Nv 1-(2-halobenzyloxy-1-indanyl)-imidazoles
ES8503669A1 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
US4634705A (en) * 1984-06-06 1987-01-06 Abbott Laboratories Adrenergic amidines
US4659730A (en) * 1984-06-18 1987-04-21 Eli Lilly And Company Aromatase inhibiting imidazole derivatives
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
FI81092C (fi) * 1986-05-15 1990-09-10 Farmos Oy Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
US4878940A (en) * 1987-04-02 1989-11-07 Janssen Pharmaceutica N.V. Herbicidal 1,5-substituted 1H-imidazoles
IL91542A0 (en) * 1988-10-06 1990-04-29 Erba Carlo Spa N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
GB9127050D0 (en) * 1991-12-20 1992-02-19 Orion Yhtymae Oy Substituted imidazole derivatives and their preparation and use
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives

Also Published As

Publication number Publication date
HU224197B1 (hu) 2005-06-28
DE69626862D1 (de) 2003-04-24
CN1198741A (zh) 1998-11-11
SK283542B6 (sk) 2003-09-11
EP0888309B1 (en) 2003-03-19
SK43998A3 (en) 1998-10-07
PL189110B1 (pl) 2005-06-30
CA2231535A1 (en) 1997-04-10
HUP9802927A3 (en) 2003-02-28
CZ291576B6 (cs) 2003-04-16
SI9620111B (en) 2001-12-31
BG102324A (en) 1999-01-29
HUP9802927A2 (hu) 1999-10-28
IL123721A0 (en) 1998-10-30
LT98057A (en) 1998-09-25
NO981496L (no) 1998-04-02
US20020007074A1 (en) 2002-01-17
CA2231535C (en) 2005-09-20
LV12108B (en) 1998-10-20
RU2188194C2 (ru) 2002-08-27
LT4460B (lt) 1999-02-25
EE04436B1 (et) 2005-02-15
RO120409B1 (ro) 2006-01-30
PL328167A1 (en) 1999-01-18
AU708002B2 (en) 1999-07-29
WO1997012874A1 (en) 1997-04-10
CN1068592C (zh) 2001-07-18
DE69626862T2 (de) 2003-12-24
DK0888309T3 (da) 2003-04-22
ES2195013T3 (es) 2003-12-01
JP4129891B2 (ja) 2008-08-06
GB9520150D0 (en) 1995-12-06
US6479530B2 (en) 2002-11-12
JP2000507914A (ja) 2000-06-27
NO981496D0 (no) 1998-04-02
NZ319169A (en) 1999-07-29
EP0888309A1 (en) 1999-01-07
US6313311B1 (en) 2001-11-06
BG63916B1 (bg) 2003-06-30
EE9800101A (et) 1998-10-15
NO311024B1 (no) 2001-10-01
AU7132796A (en) 1997-04-28
LV12108A (lv) 1998-08-20
PT888309E (pt) 2003-07-31
IL123721A (en) 2004-07-25
SI9620111A (sl) 1998-10-31
ATE234819T1 (de) 2003-04-15
CZ101898A3 (cs) 1998-09-16
HK1014951A1 (en) 1999-10-08
KR19990064013A (ko) 1999-07-26

Similar Documents

Publication Publication Date Title
UA49847C2 (uk) ПОХІДНІ ІМІДАЗОЛУ, ЩО МАЮТЬ СПОРІДНЕНІСТЬ ДО АКТИВНОСТІ &lt;font face=&#34;Symbol&#34;&gt;a&lt;/font&gt;2-РЕЦЕПТОРІВ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ
HUT70513A (en) Piperazine derivatives as 5-ht receptors antagonists, pharmaceutical compositions comprising them and method for producing thereof
PL302163A1 (en) Novel derivatives of benzimidazolone
FI20010083A (fi) P-reseptoriantagonistien synteesissä käytetyt välituotteet ja menetelmä niiden valmistamiseksi
CA2401229A1 (en) Aryl fused azapolycyclic compounds
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
MY136258A (en) 5-phenyl-pyrimidine derivatives
NZ331060A (en) Quinoxalinediones, preparation and pharmaceutical compositions thereof
TW252114B (uk)
MY122731A (en) 4-phenyl-pyrimidine derivatives
DE69512208T2 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
IL136030A0 (en) Propylisopropyl acetic acid and propylisopropyl acetamide racemic mixtures, a method for their synthesis and pharmaceutical compositions containing them
AP9801410A0 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists.
AU5674894A (en) Azanoradamantanes
HU912901D0 (en) Method for producing 3-(1h-indazole-3-yl)-4-pyridine amines and pharmaceutical preparatives containing said compounds
FR2633292B1 (fr) Nouveaux derives de la 20,21-dinoreburnamenine substitues en 15 par un groupement amine, leur procede de preparation et les intermediaires ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les reenfermant
JO1785B1 (en) Therapeutic agents
LTIP1450A (en) Azaspiroalkane derivatives,processes for their preparation and pharmaceutical compositions containing them
TH48884A (th) อนุพันธ์ 4-ฟีนิล-ไพริมิดิน